<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-133341</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Multicentric prevalence study of anti P ribosomal autoantibodies in juvenile onset systemic lupus erythematosus compared with adult onset systemic lupus erythematosus</dc:title>
<dc:description xml:lang="en">Objective. To investigate the prevalence and associations with clinical manifestations of anti- P ribosomal antibodies in patients with juvenile-onset and adult-onset systemic lupus erythematosus (SLE). Methods. Clinical and serological data of 30 patients with juvenile-onset SLE (age at onset younger than 16 years old) were compared with data of 92 patients with adult-onset SLE. Symptoms occurring during the entire disease course were considered. Anti- P ribosomal antibodies were tested by ELISA. Results. Anti- P ribosomal antibodies were found significantly more often in pediatric-onset SLE patients (26.7% vs. 6.5%; OR = 5.21 [CI95% = 1.6-16.5], p = 0.003). Alopecia (OR = 10.11, CI 95% = 1.25-97) and skin rash (non discoid) (OR = 4.1, CI 95% = 1.25-13.89) were significantly associated with anti- P ribosomal antibodies. Conclusion. Anti-ribosomal P antibodies are more often found in patients with juvenile SLE. Alopecia and skin rash were the only clinical manifestations associated to anti-ribosomal P antibodies (AU)</dc:description>
<dc:creator>Soriano, Enrique</dc:creator>
<dc:creator>Dubinsky, Diana</dc:creator>
<dc:creator>García, Mercedes</dc:creator>
<dc:creator>D'Amico, María Agustina</dc:creator>
<dc:creator>Pisoni, Cecilia N</dc:creator>
<dc:creator>Basta, María Cristina</dc:creator>
<dc:creator>Sansinanea, Pierina</dc:creator>
<dc:creator>Bresan, Eleonora</dc:creator>
<dc:creator>Muñoz, Sebastián Andrés</dc:creator>
<dc:creator>Russo, Ricardo</dc:creator>
<dc:creator>Beron, Ana</dc:creator>
<dc:creator>Carrizo, Carolina</dc:creator>
<dc:creator>Eimon, Alicia</dc:creator>
<dc:creator>Cosatti, Micaela</dc:creator>
<dc:creator>Álvarez, Analía</dc:creator>
<dc:creator>Barreira, Juan Carlos</dc:creator>
<dc:creator>Cunto, Carmen de</dc:creator>
<dc:creator>Borgia, Ezequiel</dc:creator>
<dc:creator>Lancioni, Eliana</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Determinar la prevalencia y correlación clínica de los anticuerpos antirribosomal P en lupus eritematoso sistémico (LES) juvenil y compararlos con LES del adulto. Métodos.  Se incluyeron en el estudio 30 pacientes con LES juvenil y 92 pacientes con LES del adulto. Consideramos LES de comienzo juvenil a todos aquellos pacientes que comenzaron su enfermedad antes de los 16 años. Se consideraron las manifestaciones clínicas y serológicas que presentaron los pacientes desde el diagnóstico hasta el momento de inclusión en el estudio (manifestaciones acumuladas). El anticuerpo antirribosomal P fue evaluado mediante la técnica de enzimo-inmunoensayo (ELISA). Resultados. La presencia de antirribosomal P fue significativamente mayor en el grupo de pacientes con LES juvenil comparado con LES del adulto (26,7% vs. 6,5%; OR = 5,21 [IC95% = 1,6-16,5], p = 0,003). La alopecía (OR = 10,11; IC95% = 1,25-97) y rash cutáneo (no discoide) (OR = 4,1; IC95% = 1,25-13,89) fueron las únicas manifestaciones clínicas que se asociaron en forma estadísticamente significativa con la presencia del anticuerpo antirribosomal P. Conclusión. Este estudio confirma una mayor prevalencia de anticuerpos antirribosomal P en pacientes con LES juvenil. La alopecia y el rash cutáneo fueros las únicas manifestaciones clínicas asociadas a la presencia de antirribosomal P (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);11(2): 73-77, mar.-abr. 2015. tab</dc:source>
<dc:identifier>ibc-133341</dc:identifier>
<dc:title xml:lang="es">Estudio multicéntrico de prevalencia de anticuerpos antirribosomal P en lupus eritematoso sistémico de comienzo juvenil comparado con lupus eritematoso sistémico del adulto</dc:title>
<dc:subject>^d12362^s22012</dc:subject>
<dc:subject>^d916</dc:subject>
<dc:subject>^d5175^s22012</dc:subject>
<dc:subject>^d8356^s22012</dc:subject>
<dc:subject>^d29640</dc:subject>
<dc:subject>^d6065^s22012</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d1329</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d4977^s22012</dc:subject>
<dc:subject>^d24314^s22012</dc:subject>
<dc:subject>^d10943^s22002</dc:subject>
<dc:subject>^d13079^s22012</dc:subject>
<dc:subject>^d15059^s22012</dc:subject>
<dc:subject>^d22443^s22039</dc:subject>
<dc:subject>^d8356^s22080</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d1329^s22002</dc:subject>
<dc:subject>^d22443^s22045</dc:subject>
<dc:subject>^d12678</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d28608^s22074</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d12678^s22002</dc:subject>
<dc:subject>^d11217^s22012</dc:subject>
<dc:subject>^d508^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201504</dc:date>
</metadata>
</record>
</ibecs-document>
